<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211102052949N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-12-20</date_registration>
      <primary_sponsor>Gonabad University of Medical Sciences</primary_sponsor>
      <public_title>Salicylic acid in acne vulgaris</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of 40% salicylic acid versus 30% salicylic acid with and without combination with doxycycline in the treatment of moderate acne vulgaris: a double-blinded, randomized, clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-11-29</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>99</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/59770</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: At first, people who have the Word criterion to study, after obtaining the consent of the company to study based on the selected goal, then people will be divided into three groups of intervention 1, 2 and control in the form of glass permutation blocks, Blinding description: In this study, patients and analysts will be unaware of the allocation of individuals to treatment groups.
Prior to sampling, participants will be asked not to confuse the treatment method with other people, and also to note the treatment for individuals so that the samples have the least contact with each other.</study_design>
      <phase>1</phase>
      <hc_freetext>Acne vulgaris.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:Intervention group: Patients are first examined by a dermatologist to measure the severity of their acne based on Michelson's acne score, and patients undergo standard photography. Then (recipients of 30% salicylic acid and doxycycline) treatment for 12 weeks with doxycycline 100 mg daily and peeling 30% salicylic acid will be done every two weeks. Then, once every two weeks until the end of treatment and also one month after the end of treatment, acne severity will be assessed based on Michelson's acne score, patient satisfaction, improvement based on the doctor's opinion and examination based on photography. Intervention 2: IPatients are first examined by a dermatologist to measure the severity of their acne based on Michelson's acne score, and patients undergo standard photography. Then (recipients of 40% salicylic acid and doxycycline placebo) treatment for 12 weeks with daily doxycycline placebo and 40% salicylic acid peeling will be performed every two weeks. Then, once every two weeks until the end of treatment and also one month after the end of treatment, acne severity will be assessed based on Michelson's acne score, patient satisfaction, improvement based on the doctor's opinion and examination based on photography. Intervention 3: Control group: Control group: At first, patients are examined by a dermatologist. The severity of their acne is measured based on Michelson's acne score and patients undergo standard photography. Then (recipients of 30% salicylic acid and doxycycline placebo) treatment for 12 weeks with doxycycline placebo Daily and 30% salicylic acid peeling will do once every two weeks. Then, once every two weeks until the end of treatment and also one month after the end of treatment, acne severity will be assessed based on Michelson's acne score, patient satisfaction, improvement based on the doctor's opinion and examination based on photography.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data will be provided to researchers without names and details.

When:
After completing the design and printing of the article

To whom:
All researchers and pharmaceutical companies

Conditions:
For similar research, the officials of pharmaceutical companies can access the results of the project by referring to the research vice chancellor of Gonabad University of Medical Sciences with the written consent of the vice chancellor for research.

Where to obtain:
Vice Chancellor for Research, Gonabad University of Medical Sciences

How to obtain:
Researchers can access the results of the project by referring to the Vice Chancellor for Research of Gonabad University of Medical Sciences with the written consent of the Vice Chancellor for Research.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hamideh Mohammadzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bohlol Hospital, Parastar Boulevard, Gonabad Town</address>
        <city>Gonabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۹۷۸۵۲_۹۶۹۱۷</zip>
        <telephone>+98 51 5723 6832</telephone>
        <email>Mohammadzadeh.hamideh@yahoo.com</email>
        <affiliation>Gonabad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hamideh mohammadzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bohlol Hospital, Parastar Boulevard, Gonabad Town</address>
        <city>Gonabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۹۷۸۵۲_۹۶۹۱۷</zip>
        <telephone>+98 51 5723 6832</telephone>
        <email>Mohammadzadeh.hamideh@yahoo.com</email>
        <affiliation>Gonabad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Moderate acne vulgaris(according to Vaishampayan classification)
Age greater than 12 years</inclusion_criteria>
      <agemin>12 years</agemin>
      <agemax>40 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnancy or intending to
Breastfeeding
Taking oral and topical acne medications in the last 34 day
History of allergies to the drugs used in the study
History of light sensitivity
Existence of recurrent herpes simplex infection
Presence of warts on the face and contagious molluscum in patients
Active dermatitis on the face
Having gastrointestinal disorders (especially esophagitis and gastroesophageal reflux)
History of liver and kidney diseases</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:Intervention group: Patients are first examined by a dermatologist to measure the severity of their acne based on Michelson's acne score, and patients undergo standard photography. Then (recipients of 30% salicylic acid and doxycycline) treatment for 12 weeks with doxycycline 100 mg daily and peeling 30% salicylic acid will be done every two weeks. Then, once every two weeks until the end of treatment and also one month after the end of treatment, acne severity will be assessed based on Michelson's acne score, patient satisfaction, improvement based on the doctor's opinion and examination based on photography.</i_keyword>
      <i_keyword>IPatients are first examined by a dermatologist to measure the severity of their acne based on Michelson's acne score, and patients undergo standard photography. Then (recipients of 40% salicylic acid and doxycycline placebo) treatment for 12 weeks with daily doxycycline placebo and 40% salicylic acid peeling will be performed every two weeks. Then, once every two weeks until the end of treatment and also one month after the end of treatment, acne severity will be assessed based on Michelson's acne score, patient satisfaction, improvement based on the doctor's opinion and examination based on photography.</i_keyword>
      <i_keyword>Control group: Control group: At first, patients are examined by a dermatologist. The severity of their acne is measured based on Michelson's acne score and patients undergo standard photography. Then (recipients of 30% salicylic acid and doxycycline placebo) treatment for 12 weeks with doxycycline placebo Daily and 30% salicylic acid peeling will do once every two weeks. Then, once every two weeks until the end of treatment and also one month after the end of treatment, acne severity will be assessed based on Michelson's acne score, patient satisfaction, improvement based on the doctor's opinion and examination based on photography.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Acne vulgaris. Timepoint: Observation of the number and type of facial acne vulgaris before the intervention and 12 weeks after the intervention and also one month after the intervention. Method of measurement: system Vaishampayan, Standard Photography, Michelson Acne Score.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Gonabad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-02-06</approval_date>
        <contact_name>Ethics Committee of Gonabad University of Medical Sciences</contact_name>
        <contact_address>Khorasan Razavi, Gonabad, Imam Khomeini St., Gonabad University of Medical Sciences Gonabad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
